Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly To Pay $4 Mil. To Delay Public Trial Of Prozac Patent Case

Executive Summary

Lilly will pay $4 mil. to delay a public trial of its Prozac (fluoxetine) patent defense under a settlement announced Jan. 25.

You may also be interested in...



Lilly, Barr Expect Prozac Generics In August 2001 After Appeals Court Ruling

Lilly and Barr expect generic competition to Prozac to arrive in August 2001 after an Aug. 9 Washington D.C. federal appeals court decision in favor of Barr's challenge of a fluoxetine patent.

Lilly, Barr Expect Prozac Generics In August 2001 After Appeals Court Ruling

Lilly and Barr expect generic competition to Prozac to arrive in August 2001 after an Aug. 9 Washington D.C. federal appeals court decision in favor of Barr's challenge of a fluoxetine patent.

Prozac New Prescription Share Declines; Celexa, Effexor Make Gains

Lilly Prozac's share of new prescriptions declined four percentage points year to date, according to IMS Health data.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS033573

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel